WO2009156675A2 - Nouvelles compositions dépigmentantes sous forme d'une composition anhydre sans vaseline et sans élastomère comprenant un dérivé phénolique solubilisé et un rétinoïde - Google Patents
Nouvelles compositions dépigmentantes sous forme d'une composition anhydre sans vaseline et sans élastomère comprenant un dérivé phénolique solubilisé et un rétinoïde Download PDFInfo
- Publication number
- WO2009156675A2 WO2009156675A2 PCT/FR2009/051036 FR2009051036W WO2009156675A2 WO 2009156675 A2 WO2009156675 A2 WO 2009156675A2 FR 2009051036 W FR2009051036 W FR 2009051036W WO 2009156675 A2 WO2009156675 A2 WO 2009156675A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- composition according
- retinoid
- oil
- hydroquinone
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 157
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 150000004492 retinoid derivatives Chemical class 0.000 title claims abstract description 24
- 239000003208 petroleum Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 239000013543 active substance Substances 0.000 claims abstract description 11
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 55
- 239000012071 phase Substances 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 27
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 23
- 229920001971 elastomer Polymers 0.000 claims description 23
- 239000000806 elastomer Substances 0.000 claims description 22
- 229940049654 glyceryl behenate Drugs 0.000 claims description 22
- 239000003921 oil Substances 0.000 claims description 20
- 235000019198 oils Nutrition 0.000 claims description 20
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 19
- 229960002916 adapalene Drugs 0.000 claims description 19
- CSHZYWUPJWVTMQ-UHFFFAOYSA-N 4-n-Butylresorcinol Chemical compound CCCCC1=CC=C(O)C=C1O CSHZYWUPJWVTMQ-UHFFFAOYSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 235000019271 petrolatum Nutrition 0.000 claims description 14
- 239000002562 thickening agent Substances 0.000 claims description 14
- -1 glyceryl fatty acid esters Chemical class 0.000 claims description 12
- 239000000654 additive Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000011230 binding agent Substances 0.000 claims description 8
- 150000002989 phenols Chemical class 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 8
- 239000002270 dispersing agent Substances 0.000 claims description 7
- 208000000069 hyperpigmentation Diseases 0.000 claims description 7
- 150000003626 triacylglycerols Chemical class 0.000 claims description 7
- 208000003351 Melanosis Diseases 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 239000003349 gelling agent Substances 0.000 claims description 6
- 230000003810 hyperpigmentation Effects 0.000 claims description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- 206010008570 Chloasma Diseases 0.000 claims description 4
- 239000004166 Lanolin Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
- 229940119170 jojoba wax Drugs 0.000 claims description 4
- 235000019388 lanolin Nutrition 0.000 claims description 4
- 229940039717 lanolin Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 claims description 3
- 239000012072 active phase Substances 0.000 claims description 3
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 229920002545 silicone oil Polymers 0.000 claims description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical group CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 2
- PWVUXRBUUYZMKM-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCO PWVUXRBUUYZMKM-UHFFFAOYSA-N 0.000 claims description 2
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 claims description 2
- LKVFCSWBKOVHAH-UHFFFAOYSA-N 4-Ethoxyphenol Chemical compound CCOC1=CC=C(O)C=C1 LKVFCSWBKOVHAH-UHFFFAOYSA-N 0.000 claims description 2
- 244000060011 Cocos nucifera Species 0.000 claims description 2
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 2
- 206010014970 Ephelides Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000007256 Nevus Diseases 0.000 claims description 2
- 206010064127 Solar lentigo Diseases 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 238000005299 abrasion Methods 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 2
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 235000019197 fats Nutrition 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 206010024217 lentigo Diseases 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 229960000990 monobenzone Drugs 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- 229940073665 octyldodecyl myristate Drugs 0.000 claims description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000037390 scarring Effects 0.000 claims description 2
- 229940012831 stearyl alcohol Drugs 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 125000000687 hydroquinonyl group Chemical group C1(O)=C(C=C(O)C=C1)* 0.000 claims 1
- 229940055577 oleyl alcohol Drugs 0.000 claims 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 11
- 230000000699 topical effect Effects 0.000 abstract description 7
- 239000004480 active ingredient Substances 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 19
- 239000002674 ointment Substances 0.000 description 19
- 239000000126 substance Substances 0.000 description 16
- 238000009472 formulation Methods 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 235000013824 polyphenols Nutrition 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 description 6
- 239000001993 wax Substances 0.000 description 6
- 239000004264 Petrolatum Substances 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 229940066842 petrolatum Drugs 0.000 description 5
- 229940099259 vaseline Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000007854 depigmenting agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 241001440269 Cutina Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- STORWMDPIHOSMF-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O STORWMDPIHOSMF-UHFFFAOYSA-N 0.000 description 2
- 238000003066 decision tree Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- LAWOZCWGWDVVSG-UHFFFAOYSA-N dioctylamine Chemical compound CCCCCCCCNCCCCCCCC LAWOZCWGWDVVSG-UHFFFAOYSA-N 0.000 description 2
- 239000008387 emulsifying waxe Substances 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- 150000002634 lipophilic molecules Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000003702 retinoic acid receptors Human genes 0.000 description 2
- 108090000064 retinoic acid receptors Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 229940098780 tribehenin Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- ZQCIPRGNRQXXSK-UHFFFAOYSA-N 1-octadecoxypropan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(C)O ZQCIPRGNRQXXSK-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FPZWZCWUIYYYBU-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl acetate Chemical group CCOCCOCCOC(C)=O FPZWZCWUIYYYBU-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- DGUXYDRSGSIRKZ-UHFFFAOYSA-N 4-[2-[3-tert-butyl-4-(diethylamino)phenyl]-2-hydroxyiminoethoxy]-2-hydroxybenzoic acid Chemical compound C1=C(C(C)(C)C)C(N(CC)CC)=CC=C1C(=NO)COC1=CC=C(C(O)=O)C(O)=C1 DGUXYDRSGSIRKZ-UHFFFAOYSA-N 0.000 description 1
- OVMCYQMEOOZBKP-UHFFFAOYSA-N 4-[4-[4-(propan-2-ylamino)butoxy]-3-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)phenyl]benzoic acid Chemical compound C1=C(C=2C=C3C(C(CCC3(C)C)(C)C)=CC=2)C(OCCCCNC(C)C)=CC=C1C1=CC=C(C(O)=O)C=C1 OVMCYQMEOOZBKP-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 241001553290 Euphorbia antisyphilitica Species 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000010394 Ochronosis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040825 Skin depigmentation Diseases 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- FOIVPCKZDPCJJY-JQIJEIRASA-N arotinoid acid Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C1=CC=C(C(O)=O)C=C1 FOIVPCKZDPCJJY-JQIJEIRASA-N 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
- 229940116224 behenate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000002973 irritant agent Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- FDPFDQAWKAWHMY-UHFFFAOYSA-N n-[2-(4-hydroxyphenyl)sulfanylethyl]acetamide Chemical compound CC(=O)NCCSC1=CC=C(O)C=C1 FDPFDQAWKAWHMY-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 208000029347 ochronosis disease Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940078491 ppg-15 stearyl ether Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Definitions
- Novel depigmenting compositions in the form of an anhydrous composition without vaseline and without elastomer comprising a solubilized phenolic derivative and a retinoid.
- the present invention relates to a novel cosmetic or pharmaceutical depigmenting composition in the form of an anhydrous ointment not containing petroleum jelly and without elastomer, in particular for topical application, comprising, as pharmaceutical active ingredients, a solubilized phenolic derivative and a retinoid.
- phenolic derivatives and more particularly polyphenols remain, for decades, among the most effective active.
- the therapeutic use of these agents results from the observation of skin depigmentation in workers in the rubber industry where some of these products are used as antioxidants. Since then, numerous studies have only confirmed their efficacy alone or in combination with other depigmenting agents [Jorge L. Sanchez, M.D. and Miguel Vazquez, M. International Journal of Dermatology Jan.-Feb 1982 vol 21 p55 58]. They thus appear as virtually inescapable assets in the treatment of hyperpigmentation and are therefore present in many commercial products.
- hydroquinone is the most used pharmaceutical active ingredients.
- Hydroquinone has been the subject of various patent applications, and in particular US Pat. No. 3,856,934, in which hydroquinone is in combination with retinoic acid and a corticosteroid as depigmenting composition.
- Rucinol or lucinol, or 4-butyl-resorcinol is a phenol derivative pharmaceutical active agent, polyphenol type marketed as agent for lightening brown spots related to pigmentation disorders (product Iklen ®).
- hydroquinone, the rucinol or their salts or its derivatives are solubilized in the aqueous phase of the preparation.
- reducing agents are used to combat this degradation, in particular sulfites, which are almost unavoidable.
- these antioxidants have a number of disadvantages such as skin irritation problems, odor in the formulations or destabilization of the formula related to a loss of viscosity.
- Hydroquinone because of its high concentration of irritating effect can cause post-inflammatory hypermelanosis and ochronosis phenomena.
- hydroquinone Treatment with hydroquinone may be accompanied by irritation that may lead to post-inflammatory hyperpigmentation.
- the incidence of irritation depends on the hydroquinone concentration. The latter is quite important for the 10% concentrations and strongly decreases for the 5% preparations and would be practically nil at the 2% concentration ["The chemical depigmenting agents" JP. Ortonne Ann. Dermatol. Venerol. 1986, 13: 733-736].
- the galenic chosen can therefore play a leading role in minimizing these effects.
- the phenolic derivative pharmaceuticals and in particular hydroquinone or rucinol in solubilized form should be formulated in a formulation to avoid the presence of sulfites and / or to suppress or limit the use of antioxidants.
- anhydrous composition without petroleum jelly and without elastomer has a sufficiently high viscosity.
- compositions currently available on the market, or as described in the application US2006 / 0120979 and allowing the formulation of active principles sensitive to water, while ensuring a good chemical stability are generally ointment-type compositions made up mainly of petroleum jelly or, in more recent formulations of a large part of elastomer.
- the use of petrolatum is not satisfactory for the following reasons: after application, certain compositions comprising petroleum jelly are perceived as sticky and greasy, and are brighter; moreover, the preparation of compositions in the form of ointments based on petroleum jelly requires particular compounds and conditions. Indeed, vaseline is solid at room temperature, and has a melting point of greater than 40 ° C.
- elastomer in a relatively large amount makes it possible to give a certain viscosity to anhydrous formulations (patent US2006 / 0120979) without the disadvantages of petroleum jelly.
- elastomer in the present invention, its use is not satisfactory for the following reasons: the high proportion of elastomer present in these formulations prevents the incorporation of sufficient quantities of oily and waxy compounds having the advantage of conferring the preparation the desired emollient properties.
- One of the aims of the present invention is to provide an anhydrous pharmaceutical composition without vaseline and without elastomer, intended for topical application, which has a viscosity equivalent to that of ointments containing vaseline, which is easy to prepare, which ensures good chemical stability of the actives and in which certain volatile compounds can be used.
- the composition according to the invention has in particular these advantages thanks to its preparation process.
- the invention therefore also relates to the particularly advantageous method of preparation of such a composition, wherein the step of incorporating the active ingredients is carried out at room temperature.
- the desired viscosity of the composition according to the invention is obtained, in particular by means of the choice of the fatty substances used.
- Another object of the present invention is to provide an anhydrous pharmaceutical composition without vaseline and without elastomer for topical application having a prolonged stability, allowing optimized release of the active ingredients while being very well tolerated.
- the present invention thus relates to a novel stable composition in the form of an anhydrous composition containing no petrolatum and without elastomer, especially for topical application, comprising, as pharmaceutical active ingredients, a phenol derivative of the solubilized polyphenol type and a retinoid.
- the anhydrous composition according to the present invention also has both excellent stability and safety.
- elastomer polyorganosiloxane elastomer.
- anhydrous composition is meant a composition comprising a quantity of water less than or equal to 5% by weight relative to the total weight of the composition.
- the composition does not contain water.
- stable composition is meant a chemically and physically stable composition.
- chemical stability it is meant in particular that no degradation of the active substance is observed over time and at temperatures of between 4 and 40 ° C.
- physical stability it is meant in particular that the compositions do not exhibit a fall in viscosity over time and at temperatures between 4 and 40 ° C.
- the object of the present invention is thus an anhydrous pharmaceutical composition, characterized in that it comprises: a. at least one first phenolic derivative pharmaceutical active agent, b. at least one second retinoid-type pharmaceutical active agent, c. glyceryl behenate, its derivatives or mixtures thereof, d. at least one solvent of the phenolic derivative, said composition containing neither petroleum jelly nor polyorganosiloxane elastomer.
- the anhydrous composition according to the invention may be in the various known galenic forms which the person skilled in the art will adapt to the particular use of the composition.
- compositions according to the invention are preferably formulated for topical application.
- topical means an external application on the skin or mucous membranes.
- compositions according to the invention may be in any of the galenical forms normally used for topical administration.
- the compositions as described in the pharmacopoeias USP32-NF27 - Chap ⁇ 1 151> - Pharmaceutical Dosage Forms
- the compositions according to the invention can therefore be in liquid, semi-solid, pasty or solid form and, more particularly, in the form of ointments, oily solutions, optionally biphasic lotion-type dispersions, serum, anhydrous or lipophilic gels, powders, soaked swabs, syndets, wipes, sprays, foams, sticks, shampoos, compresses, washing bases, emulsions of liquid or semi-liquid consistency of the oil type in glycol or glycol in oil, a microemulsion, suspensions or semi-liquid or solid emulsion
- the anhydrous composition according to the invention is preferably an ointment.
- Ointment according to the invention means a particular composition as defined in the American or European pharmacopoeia mentioned above.
- the FDA thus defines the ointment as a semi-solid composition comprising, as a carrier, less than 20% water and volatile compounds and more than 50% hydrocarbons, waxes, or polyol. In some cases, when volatile levels are important such compositions may be called creams (American Food and Drug Administration (FDA) decision tree).
- FDA American Food and Drug Administration
- the American Pharmacopoeia defines an ointment as a product whose base is a vehicle that can belong to the following 4 classes: hydrocarbon base or absorbent base or water-washable base or water-soluble base.
- the ointment as defined in the American Pharmacopoeia is of the hydrocarbon base type.
- the European Pharmacopoeia defines ointment as a single-phase composition in which liquids or solids can be dispersed.
- the ointment according to the invention is a thick composition at room temperature, which comprises between 80 and 98% by weight relative to the total weight of the composition of hydrophobic compounds distinct from petroleum jelly.
- Such compounds are chosen in particular from liquid oils alone or as a mixture, said oils, which may be volatile or nonvolatile hydrocarbons, esters, vegetable oils and / or silicone oils, which may be gelled by solid-phase lipophilic compounds such as waxes, butters, fatty acid esters; .
- a flow threshold measurement may be performed to characterize the finished product.
- a HAAKE rheometer of type VT550 with a measurement mobile SVDIN was used.
- the rheograms are produced at 25 ° C and imposed speed from 0 to 100 s "1.
- the viscosity values are given to the shear values of 4 s" 1, 20s “1 100s” 1 ( ⁇ ).
- flow threshold ⁇ 0 expressed in Pascal
- ⁇ 0 expressed in Pascal is meant the force required (minimum shear stress) to overcome Van der Waals cohesive forces and cause flow.
- ambient temperature means a temperature between 20 and 30 ° C.
- the anhydrous nature of the ointment containing no petrolatum or elastomer according to the invention makes it possible to avoid the instability of the phenol derivative, in particular its oxidation in an aqueous medium.
- the use of sulphite type antioxidants essential for the stabilization of hydroquinone in an aqueous medium is therefore no longer necessary. Therefore, in a preferred embodiment according to the invention, the composition does not contain sulfites and contains an amount of antioxidants strictly less than 0.3% by weight relative to the total weight of the composition, preferably less than 0.2%.
- antioxidants that can be used according to the invention are preferably antioxidants such as vitamin E and its derivatives, such as DL alpha Tocopherol or Roche tocopherol acetate; vitamin C and its derivatives, such as Roche's Ascorbyl Palmitate, butylhydroxytoluene sold under the name Nipanox BHT by Clariant.
- vitamin E and its derivatives such as DL alpha Tocopherol or Roche tocopherol acetate
- vitamin C and its derivatives such as Roche's Ascorbyl Palmitate, butylhydroxytoluene sold under the name Nipanox BHT by Clariant.
- the anhydrous ointment according to the invention comprises: at least one first solubilized phenolic derivative pharmaceutical active ingredient, at least one first retinoid-type pharmaceutical active ingredient, glyceryl behenate and / or derivatives and / or their mixtures, optionally, at least one additional lipophilic thickener or gelling agent, at least one solvent of the phenolic derivative, optionally at least one solvent or dispersant of the retinoid, and optionally at least one fatty substance or oil.
- the anhydrous composition according to the invention contains substantially no petrolatum, ie comprises at most 1% by weight of petrolatum relative to the total weight of the composition.
- rucinol salts is intended especially to mean salts formed with a pharmaceutically acceptable base, in particular a mineral base such as sodium hydroxide, potassium hydroxide and aqueous ammonia, or an organic base such as lysine, arginine, N-methyl- glucamine, but also the salts formed with fatty amines such as dioctylamine, aminomethyl propanol and stearylamine.
- a pharmaceutically acceptable base such as sodium hydroxide, potassium hydroxide and aqueous ammonia
- organic base such as lysine, arginine, N-methyl- glucamine, but also the salts formed with fatty amines such as dioctylamine, aminomethyl propanol and stearylamine.
- hydroquinone or rucinol is used.
- the amount of pharmaceutical active ingredient of the phenol derivative type is from 0.01 to 10% by weight relative to the total weight of the composition, preferably from 0.05 to 6% by weight and more particularly from 0.1 to 10% by weight. 5% by weight.
- the composition comprises, as a second pharmaceutical active ingredient, a retinoid.
- Retinoid means any compound binding to receptors (retinoic acid receptors (RARs) and / or retinoic X receptors (RXRs)) as well as their precursors and derivatives.
- RARs retinoic acid receptors
- RXRs retinoic X receptors
- the retinoids that can be used in the context of the invention include in particular all-trans retinoic acid or tretinoin, 13-cis-retinoic acid or isotretinoin, acitretin, arotinoic acid, retinol, tazarotene, retinaldehyde, etretinate and the compounds protected in patent applications EP 0 199 636, US 4,666,941, US 4,581,380, EP 0 210 929, EP 0 232 199, EP 0 260 162 and EP 0 292 348, EP 0 325 540, EP 0 359 621, EP 0 409 728, EP 0 409 740, EP 0 552 282, EP 0 584 191, EP 0 514 264, EP 0 514 269, EP 0 661 260, EP 0 661 258, EP 0 658 553, EP 0 679 628, EP 0 679 631, EP 0 679
- adapalene and its salts are preferred, and 3 "-tert-butyl-4 '- (2-hydroxyethoxy) -4" -pyrrolidin-1-yl- [1, 1'; 3 ', 1 "] terphenyl-4-carboxylic acid.
- Suitable salts of adapalene are in particular salts formed with a pharmaceutically acceptable base, in particular mineral bases such as sodium hydroxide, potassium hydroxide and aqueous ammonia or organic bases such as lysine, arginine, N- methylglucamine, and salts formed with fatty amines such as dioctylamine and stearylamine.
- retinoid precursors are meant their immediate biological precursors or substrates, as well as their chemical precursors.
- Derivatives of retinoids include both their metabolic derivatives and their chemical derivatives.
- the composition comprises an amount of retinoid agent of between 0.0001 and 1% by weight relative to the total weight of the composition, preferably between 0.001 and 0.5%, even more preferably between 0.01 and 0.3%. in weight.
- the composition according to the invention comprises glyceryl behenate, its derivatives or their mixtures.
- Derivatives of glyceryl behenate include but are not limited to glyceryl monobhenate, glyceryl dibenenate, tribehenin.
- the composition according to the invention preferably comprises, in a preferred manner, the mixture of glyceryl dibenenate, tribehenin and glyceryl behenate. Such a mixture is especially marketed under the name Compritol 888 by Gattefossé.
- glyceryl behenate is understood to mean glyceryl behenate, its derivatives or their mixtures.
- Glyceryl behenate is an oily phase thickener.
- the glyceryl behenate is en masse in time and makes it possible to prepare a hydrophobic composition whose final viscosity is obtained only after a certain time.
- the constituents and the process are indeed chosen so as to impart fluidity to the composition at the end of immediate manufacture, facilitating the homogenization of the various constituents, but a final viscosity sought for about 24 hours following the manufacturing.
- the composition comprises from 1 to 40%, preferably from 5 to 30%, and even more preferably from 10 to 25% by weight relative to the total weight of the composition of glyceryl behenate.
- composition according to the invention may also comprise at least one lipophilic gelling agent, or else called additional lipophilic thickener.
- a gelling agent or additional lipophilic thickener provides a better physical stability to the composition, in particular when the latter is subjected to accelerated conditions of stability (ICH criteria) at around 40 ° C.
- these compounds are used in the present invention as "viscosity adjusters": in particular, by choosing them judiciously, they ensure the stability of the composition at 40 ° C. This therefore gives a better stability to the compositions obtained.
- Additional lipophilic thickeners or gelling agents according to the invention are compounds which are distinct from glyceryl behenate, chosen in particular from waxes, fatty alcohols, hydrogenated oils and fatty acid esters.
- wax is generally meant a lipophilic compound, solid at room temperature (25 ° C.), with a reversible solid / liquid state change, having a melting point of greater than or equal to 30 ° C. and up to at 200 0 C and in particular up to 120 0 C.
- waxes that can be used mention may be made of carnauba wax, microcrystalline waxes, beeswax, marketed under the name White Cerabeil by Barlocher, or wax of candelilla.
- Hydrogenated oil is understood to mean the oils obtained by catalytic hydrogenation of animal or vegetable oils having linear or branched C 8 -C 32 fatty chains.
- hydrogenated jojoba oil isomérz jojoba oil such as trans isomerized partially hydrogenated jojoba oil manufactured or marketed by Desert Whale under the trade reference ISO-JOJOBA-50 ® , hydrogenated sunflower oil, hydrogenated castor oil, marketed in particular under the name Cutina HR by
- hydrogenated coconut oil and hydrogenated lanolin oil preferably, the hydrogenated castor oil will be used.
- the composition comprises a total amount of glyceryl behenate and optionally additional lipophilic thickeners or gelling agents of between 1 and 40% by weight relative to the total weight of the composition, preferably between 5 and 35%.
- the composition comprises from 10 to 25% by weight of glyceryl behenate, and from 0 to 30% by weight of additional lipophilic thickener, preferably from 1 to 10%.
- composition without elastomer according to the invention is meant an anhydrous composition comprising at most 1% by weight of elastomer relative to the total weight of the composition.
- the ointment according to the invention does not contain an elastomer.
- elastomer is understood to mean any polyorganosiloxane elastomer, namely any chemically crosslinked siloxane polymer which has viscoelastic properties. Indeed, the desired viscosity of the composition according to the invention is obtained using, in particular, glyceryl behenate and the choice of other fatty substances used.
- the absence of elastomer within the composition makes it possible, in particular, to introduce more oily compounds thus conferring on the composition the desired emollient properties.
- the absence of elastomer makes it possible in particular to obtain the effect of the more marked glycenyl behenate, namely, a fluidity of the composition at the end of manufacture and a final viscosity reached about 24 hours after manufacture.
- the composition also comprises at least one solvent of the phenolic derivative pharmaceutical active ingredient.
- solvent of the phenolic derivative is meant in particular solvents of alcoholic or glycolic type.
- composition according to the invention preferentially contains ethanol.
- glycolic type solvent include for example propylene glycol, ethylene glycol, 1,3-butylene glycol and dipropylene glycol.
- the solvents of the phenolic derivative of alcoholic or glycolic type that are preferred according to the invention are in particular ethanol and propylene glycol.
- the solvent of the phenolic derivative pharmaceutical active ingredient is ethanol.
- the total amount of solvent is between 1 and 80% by weight, preferably between 5 and 50% and more particularly between 10 and 30% by weight, relative to the total weight of the composition.
- the composition also comprises at least one solvent or dispersant of the retinoid.
- the solvent or dispersant of the retinoid may be oily, alcoholic or glycolic type.
- the alcoholic or glycolic solvents may be of the type described above.
- the oily solvents or dispersants may be of any type known to those skilled in the art, in particular mineral, vegetable oils, esters or triglycerides.
- the preferred retinoid is adapalene and is therefore present in dispersed form.
- the preferred dispersant of the adapalene according to the invention is preferably of oily type, and more particularly of triglycerides such as Caprylic / Caprique Triglycerides sold under the name Miglyol 812 N by IMCD or glycolic type, such as propylene glycol.
- the total amount of solvent or dispersant of the retinoid is between 1 and 80% by weight, and preferably between 1 and 60% by weight, relative to the total weight of the composition.
- fatty substances or oil selected from the following list:
- oils such as sweet almond oil sold by Sictia or sesame oil sold by CPF, silicone oils such as cyclomethicone sold under the name ST-Cyclomethicone 5NF by Dow Corning or Dimethicone sold under the name of Q7 9120 silicon fluid by Dow corning,
- mineral oils such as Marcol 152 or Primol 352 sold by Esso,
- triglycerides such as Caprylic / Caprique Triglycerides sold under the name Miglyol 812 N by IMCD, or derivatives such as PEG-8 Caprylic Capric Triglycerides sold under the name Labrasol by the company Gattefossé,
- esters such as the Octyl Dodecyl Myristate sold under the name MOD by Gattefossé, the C12-C15 alkyl benzoate sold under the name Tegosoft TN by Goldschmit or the cetearyl isononanoate sold under the name Cetiol SN PH by Cognis ,
- guerbet alcohols such as octyldodecanol sold under the name Eutanol G by Cognis,
- compositions according to the invention When at least one fatty substance or oil is present in the composition, their amount is between 0.05 and 98% by weight, preferably between 1 and 80% by weight.
- the composition according to the invention may also comprise at least one surfactant, and / or at least one binder.
- the surfactants used are preferably nonionic surfactants, used for example, but not exclusively, to facilitate the incorporation of certain constituents such as glycols into the oily phase of the composition.
- glyceryl and optionally polyethylene glycol esters such as the mixture of glyceryl stearate and PEG-100 stearate, sold under the name Arlacel 165 by Uniqema, the mixture glyceryl stearate and PEG-75 stearate, sold under the name Gelot 64 by Gattefossé, glyceryl stearate sold under the name Cutina GMSV by Cognis; emulsifying waxes, such as the self-emulsifying wax sold under the name of Polawax NF by Croda, or the PEG-8 beeswax sold under the name of Apifil by Gattefossé; polysorbate 80 sold under the name Tween 80 by Uni
- the composition may also comprise at least one binder.
- binders that can be used are magnesium stearate sold by Brenntag, corn starch sold by Roquette, talc sold by WCD, cholesterol sold by Croda or silica sold by Degussa.
- the binders can be used in an amount of between 1 and 30% by weight, preferably between 1 and 20% by weight.
- composition according to the invention may also contain additives between 0 and 20%, preferably between 0 and 10% by weight relative to the total weight of the composition, additives that the man of the art will choose according to the desired effect.
- additives for example, taken alone or in combination:
- vitamins such as vitamin PP or niacinamide
- soothing and / or anti-irritant agents such as the PPG-12 / SMDI copolymer sold by Bertek pharmaceuticals under the trade name Polyolprepolymer-2 or glycyrrhetinic acid or its derivatives, for example Enoxolone sold by Cognis, or hyaluronic acid,
- moisturizing or humectant agents for example, sugars and derivatives, glycols, glycerin, sorbitol,
- preservatives such as paraben methyl sold under the name Nipagin M by Clariant, propyl paraben sold under the name Nipasol by Clariant, or phenoxyethanol sold under the name phenoxetol by Clariant,
- acids or bases such as citric acid, sodium citrate, triethanolamine, aminomethylpropanol, sodium hydroxide, diisopropanolamine,
- composition according to the invention comprises, by weight relative to the total weight:
- composition according to the invention comprises, by weight relative to the total weight:
- composition according to the invention comprises, by weight relative to the total weight: 0.01 to 5% of hydroquinone or of rucinol,
- the invention also relates to the use of the composition thus obtained as a medicament.
- the composition can be used to prepare a medicament for the treatment and prevention of hyperpigmentary disorders such as melasma, chloasma, lentigines, senile lentigo, vitiligo, freckles, post-inflammatory hyperpigmentations.
- hyperpigmentary disorders such as melasma, chloasma, lentigines, senile lentigo, vitiligo, freckles, post-inflammatory hyperpigmentations.
- hyperpigmentary disorders such as melasma, chloasma, lentigines, senile lentigo, vitiligo, freckles, post-inflammatory hyperpigmentations.
- the subject of the invention is also the use of the composition in the cosmetic field.
- compositions according to the invention also find application in the cosmetics field, in particular in the protection against the harmful aspects of the sun, for preventing and / or for combating photoinduced or chronological aging of the skin and superficial body growths.
- the invention also relates to a non-therapeutic cosmetic treatment method for beautifying the skin and / or improving its surface appearance, characterized in that a composition comprising adapalene and at least one depigmenting agent is applied to the skin and / or its integuments.
- the subject of the present invention is also a process for the preparation of the compositions according to the invention.
- Such a method allows in particular the maintenance of the compounds in the fluid state at the end of manufacture.
- One of the essential characteristics of the process for preparing the compositions according to the invention is the incorporation of the active phase at ambient temperature, that is to say that the final step of mixing the phases is carried out at room temperature.
- ambient temperature is meant a temperature of between 20 and 30 ° C.
- active phase a phase containing at least one active ingredient.
- non-active phase a phase consisting of any other ingredient different from the active ingredient.
- the non-active phase is preferably an oily phase containing at least glyceryl behenate, preferably with another oily compound as described above.
- the process for producing the composition according to the invention is carried out according to Example 1, characterized in that the phases containing the pharmaceutical active ingredients are mixed at room temperature.
- the mixture of the active and non-active phases at room temperature avoids the volatilization of the solvent (s) and the degradation of the active agents, potentially sensitive to heat, in particular the phenolic derivatives such as hydroquinone or rucinol.
- the examples of formulations below make it possible to illustrate the compositions according to the invention, without however limiting the scope thereof.
- the amounts of the constituents are expressed in% by weight relative to the total weight of the composition.
- phase A Preparation of the fat phase or non-active phase (phase A):
- phase B Solubilize the retinoid in the appropriate solvent, (phase B)
- phase B If presence of a retinoid dispersed in the composition, for example adapalene, weigh at this stage, adapalene in an oily liquid, and disperse under high shear (phase B).
- a retinoid dispersed in the composition for example adapalene
- the active phase (s) at the base form at room temperature, for the solubilizations in ethanolic or glycolic phase. Incorporate additional phases as needed.
- the packaging is made at the end of manufacture because the product does not yet have its final viscosity.
- the physical stability is measured by a macroscopic and microscopic observation of the formulation at ambient temperature, at 4 ° C. and at 40 ° C. after 1 month, 2 months and optionally 3 months and 6 months of storage.
- the macroscopic observation makes it possible to guarantee the physical integrity of the products and the microscopic observation makes it possible to verify that there is no recrystallization of the solubilized active agent.
- the chemical stability is measured by assaying the active ingredients by external calibration in HPLC and the results are expressed in% recovery relative to the value obtained at TO or relative to the theoretical title.
- Macroscopic appearance thick and supple ointment, white
- Macroscopic appearance Thick and supple ointment, white with light yellow reflections
- Microscopic aspect Absence of hydroquinone crystals, adapalene dispersion of ⁇ 2.5 ⁇ m at 5 ⁇ m.
- Macroscopic appearance Thick and supple ointment, white with light yellow reflections
- Microscopic aspect Absence of hydroquinone crystals, adapalene dispersion of ⁇ 2.5 ⁇ m at 5 ⁇ m. Physical stability:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09769516A EP2293788A2 (fr) | 2008-05-30 | 2009-06-02 | Nouvelles compositions dépigmentantes sous forme d'une composition anhydre sans vaseline et sans élastomère comprenant un dérivé phénolique solubilisé et un rétinoïde |
CA2723435A CA2723435A1 (fr) | 2008-05-30 | 2009-06-02 | Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise et un retinoide |
US12/994,459 US20110152372A1 (en) | 2008-05-30 | 2009-06-02 | Anhydrous petroleum jelly/elastomer-free depigmenting compositions comprising a solubilized phenolic compound and a retinoid |
MX2010012754A MX2010012754A (es) | 2008-05-30 | 2009-06-02 | Nuevas composiciones despigmentantes bajo la forma de una composicion anhidra sin vaselina y sin elastomero que comprenden un derivado fenolico solubilizado y un retinoide. |
CN2009801200318A CN102046161A (zh) | 2008-05-30 | 2009-06-02 | 包含溶解的酚衍生物和类维生素a的呈无矿脂和无弹性体的无水组合物形式的新型去色素组合物 |
JP2011511070A JP2011521933A (ja) | 2008-05-30 | 2009-06-02 | 可溶化フェノール誘導体およびレチノイドを含むワセリンフリーかつエラストマーフリーの無水組成物の形態の新規な脱色素沈着組成物 |
AU2009264011A AU2009264011A1 (en) | 2008-05-30 | 2009-06-02 | Novel depigmenting compositions in the form of a petroleum jelly-free and elastomer-free anhydrous composition comprising a solubilized phenolic derivative and a retinoid |
KR1020107029553A KR20110015027A (ko) | 2008-05-30 | 2009-06-02 | 가용화 페놀성 유도체 및 레티노이드를 포함하는 석유 젤리-부재 및 엘라스토머-부재 무수 조성물 형태의 신규 탈색 조성물 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0853567 | 2008-05-30 | ||
FR0853567A FR2931661B1 (fr) | 2008-05-30 | 2008-05-30 | Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise et un retinoide. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009156675A2 true WO2009156675A2 (fr) | 2009-12-30 |
WO2009156675A3 WO2009156675A3 (fr) | 2010-04-08 |
Family
ID=40193547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2009/051036 WO2009156675A2 (fr) | 2008-05-30 | 2009-06-02 | Nouvelles compositions dépigmentantes sous forme d'une composition anhydre sans vaseline et sans élastomère comprenant un dérivé phénolique solubilisé et un rétinoïde |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110152372A1 (fr) |
EP (1) | EP2293788A2 (fr) |
JP (1) | JP2011521933A (fr) |
KR (1) | KR20110015027A (fr) |
CN (1) | CN102046161A (fr) |
AU (1) | AU2009264011A1 (fr) |
CA (1) | CA2723435A1 (fr) |
FR (1) | FR2931661B1 (fr) |
MX (1) | MX2010012754A (fr) |
RU (1) | RU2010154235A (fr) |
WO (1) | WO2009156675A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150147403A1 (en) * | 2012-06-01 | 2015-05-28 | Galderma Research & Development | Dermatological composition comprising oleosomes and retinoids, process for preparing the same and use thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6552350B2 (ja) * | 2015-09-08 | 2019-07-31 | 株式会社マンダム | 油性ヘアトリートメント組成物 |
CN109789066A (zh) * | 2016-06-30 | 2019-05-21 | 西姆莱斯股份公司 | 含有间苯二酚衍生物的药物和化妆组合物 |
US11331254B2 (en) * | 2018-09-25 | 2022-05-17 | L'oreal | Compositions for providing a protective barrier |
US11278479B2 (en) | 2018-09-25 | 2022-03-22 | L'oreal | Moisturizing anhydrous butter balm composition and method |
KR102585664B1 (ko) * | 2023-04-17 | 2023-10-05 | 허훈 | 미백 화장품 조성물 |
Citations (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3856934A (en) | 1970-06-24 | 1974-12-24 | A Kligman | Skin depigmentation |
US4581380A (en) | 1983-11-28 | 1986-04-08 | Groupement Economique dite: Centre National de Recherches Dermatologiques C.I.R.D. | 2,6-disubstituted naphthalene derivatives, a process for preparing the same and pharmaceutical and cosmetic compositions containing the same |
EP0199636A1 (fr) | 1985-04-11 | 1986-10-29 | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. Groupement d'Intérêt Economique dit: | Dérivés benzonaphtaléniques, leur procédé de préparation et leur application dans les domaines pharmaceutique et cosmétique |
EP0210929A2 (fr) | 1985-07-25 | 1987-02-04 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Dérivés aromatiques polycycliques, leur procédé de préparation et leur application dans les domaines pharmaceutique et cosmetique |
EP0232199A2 (fr) | 1986-01-21 | 1987-08-12 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Composés benzamido aromatiques, leur procédé de préparation et leur utilisation en médecine humaine ou vétérinaire et en cosmétique |
EP0260162A1 (fr) | 1986-07-17 | 1988-03-16 | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA Groupement d'Intérêt Economique dit: | Dérivés bicycliques aromatiques, leur procédé de préparation et leur utilisation en médecine humaine et vétérinaire et en cosmétique |
EP0292348A1 (fr) | 1987-04-30 | 1988-11-23 | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA Groupement d'Intérêt Economique dit: | Dérivés hétérocycliques polycycliques , leur procédé de préparation et leur utilisation en médecine humaine et vétérinaire |
EP0325540A1 (fr) | 1988-01-20 | 1989-07-26 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Esters et thioesters aromatiques, leur procédé de préparation et leur utilisation en médecine humaine ou vétérinaire et en cosmétique |
EP0359621A1 (fr) | 1988-09-01 | 1990-03-21 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Nouveau composé marqué au tritium, sa préparation et son application notamment dans la détermination de l'affinité des rétinoides pour leurs récepteurs nucléaires et leur protéine de liaison cytosolique |
EP0409740A1 (fr) | 1989-07-20 | 1991-01-23 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveau composÀ© marqué au tritium, sa préparation et son application, notamment dans le repÀ©rage des récepteurs nucléaires des rétinoides |
EP0409728A2 (fr) | 1989-07-18 | 1991-01-23 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Esters bi-aromatiques, leur procédé de préparation et leur utilisation en médecine humaine ou vétérinaire et en cosmétique |
EP0514269A1 (fr) | 1991-05-15 | 1992-11-19 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveaux composés aromatiques dérivés d'imine, leur procédé de préparation et leur utilisation en médecine humaine et vétérinaire ainsi qu'en cosmétique |
EP0514264A1 (fr) | 1991-05-13 | 1992-11-19 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Composés bi-aromatiques dérivés d'un motif salicylique, leur procédé de préparation et leur utilisation en médecine humaine et vétérinaire ainsi qu'en cosmétique |
EP0552282A1 (fr) | 1990-10-12 | 1993-07-28 | Cird Galderma | Composes bi-aromatiques et leur utilisation en medecine humaine et veterinaire et en cosmetique. |
EP0584191A1 (fr) | 1991-05-02 | 1994-03-02 | Cird Galderma | Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique. |
EP0658553A1 (fr) | 1993-12-15 | 1995-06-21 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0661258A1 (fr) | 1993-12-15 | 1995-07-05 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveaux composés propynyl bi-aromatiques, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0661260A1 (fr) | 1993-12-15 | 1995-07-05 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveaux composés bi-aromatiques dérivés d'amide, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0679628A1 (fr) | 1994-04-26 | 1995-11-02 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés polyéniques, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0679631A1 (fr) | 1994-04-26 | 1995-11-02 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Composés bi-aromatiques acétylénés à groupement adamantyle, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0679630A1 (fr) | 1994-04-26 | 1995-11-02 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés bicycliques-aromatiques, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0708100A1 (fr) | 1994-10-04 | 1996-04-24 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveaux composés dérivés du dibenzofuranne, compositions pharmaceutiques et cosmétiques les contenant |
EP0709382A1 (fr) | 1994-10-28 | 1996-05-01 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveaux composés dérivés aromatiques du dibenzofuranne, compositions pharmaceutiques et cosmétiques les contenant |
EP0722928A1 (fr) | 1995-01-20 | 1996-07-24 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés bicycliques-aromatiques à forte activité biologique, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0728739A1 (fr) | 1995-02-23 | 1996-08-28 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés bi-aromatiques dérivés d'amide, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0732328A1 (fr) | 1995-03-14 | 1996-09-18 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés hétérocycliques aromatiques, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0740937A2 (fr) | 1995-05-03 | 1996-11-06 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Utilisation de rétinoides pour la fabrication d'une composition cosmétique ou pharmaceutique |
EP0776881A1 (fr) | 1995-12-01 | 1997-06-04 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés biaromatiques portant un groupement adamantyl en para, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0776885A1 (fr) | 1995-12-01 | 1997-06-04 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés biaromatiques portant un groupement adamantyl en ortho, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0816352A1 (fr) | 1996-06-28 | 1998-01-07 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Nouveaux composés biaryles hétérocycliques et leur utilisation en médecine humaine ou vétérinaire ainsi qu'en cosmétique |
EP0823903A1 (fr) | 1996-02-06 | 1998-02-18 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
EP0826657A1 (fr) | 1996-09-02 | 1998-03-04 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveaux composés modulateurs des récepteurs hormonaux, les compositions les comprenant et leur utilisation en thérapie |
EP0832057A1 (fr) | 1996-03-14 | 1998-04-01 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composes propynyl ou dienyl biaromatiques |
EP0832081A1 (fr) | 1996-03-14 | 1998-04-01 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Compos s bicycliques-aromatiques |
EP0850909A1 (fr) | 1996-12-31 | 1998-07-01 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés stilbéniques à groupement adamantyl, compositions les contenant et utilisations |
EP0874626A1 (fr) | 1996-09-20 | 1998-11-04 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation |
EP0879814A1 (fr) | 1997-05-23 | 1998-11-25 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés triaromatiques, compositions les contenant et utilisations |
EP0882033A1 (fr) | 1996-12-04 | 1998-12-09 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Derives d'acides benzofuranne-acryliques et leur utilisation comme modulateurs des recepteurs rxrs ou rars |
WO1998056783A1 (fr) | 1997-06-13 | 1998-12-17 | Galderma Research & Development | Composes bi-aromatiques et compositions pharmaceutiques et cosmetiques les contenant |
WO1999010322A1 (fr) | 1997-08-21 | 1999-03-04 | Galderma Research & Development | Composes bi-aromatiques relies par un radical heteroethynylene et compositions pharmaceutiques et cosmetiques les contenant |
EP0905118A1 (fr) | 1997-09-25 | 1999-03-31 | Galderma Research & Development, S.N.C. | Dérivés insaturés en position 4 du 6-tert-butyl-1,1-diméthylindane et leur utilisation en médicine humaine ou vétérinaire ainsi qu'en cosmétique |
EP0915823A1 (fr) | 1996-11-19 | 1999-05-19 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
EP0934295A1 (fr) | 1996-10-23 | 1999-08-11 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Nouveaux derives bi-aromatiques du dibenzofuranne et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetique |
EP0947496A1 (fr) | 1998-03-31 | 1999-10-06 | Galderma Research & Development, S.N.C. | Composés bicycliques-aromatiques et leur utilisation en médecine humaine ou vétérinaire ainsi qu'en cosmétologie |
WO1999050239A2 (fr) | 1998-03-31 | 1999-10-07 | Galderma Research & Development, S.N.C. | Nouveaux composes heteroethynylenes et compositions pharmaceutiques et cosmetiques les contenant |
EP0952974A1 (fr) | 1997-08-21 | 1999-11-03 | Galderma Research & Development | Derives biphenyliques substitues par un radical aromatique ou heteroaromatique et compositions pharmaceutiques et cosmetiques les contenant |
WO1999065872A1 (fr) | 1998-06-12 | 1999-12-23 | Galderma Research & Development, S.N.C. | Composes diarylselenures et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetologie |
WO2005037772A2 (fr) | 2003-10-17 | 2005-04-28 | Galderma Research & Development, S.N.C. | NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS RARs, UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE |
WO2005056510A2 (fr) | 2003-12-08 | 2005-06-23 | Galderma Research & Development, S.N.C. | Nouveaux ligands activateurs des recepteurs rar s'utilisant en medecine et en cosmetique |
WO2005056516A1 (fr) | 2003-12-08 | 2005-06-23 | Galderma Research & Development, S.N.C. | Derives biphenyles utiles en tant que ligands d'activation des recepteurs rar, leur procede de preparation et leur utilisation en medecine humaine et en cosmetique |
US20060120979A1 (en) | 2004-12-02 | 2006-06-08 | Joel Rubin | Skin care composition comprising hydroquinone and a substantially anhydrous base |
WO2006066978A1 (fr) | 2004-12-23 | 2006-06-29 | Galderma Research & Development | Nouveaux ligands qui modulent les recepteurs rar, et leur utilisation en medecine et en cosmetique |
WO2007066041A2 (fr) | 2005-12-06 | 2007-06-14 | Galderma Research & Development | Composition dépigmentante de la peau comprenant un dérivé d'acide naphtoique |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2598420B1 (fr) * | 1986-05-06 | 1991-06-07 | Oreal | Nouveaux esters retinoiques d'antibiotiques, leur procede de preparation et compositions pharmaceutiques et cosmetiques les contenant |
AU8144698A (en) * | 1997-06-20 | 1999-01-04 | Mary Kay Inc. | Cosmetic composition containing a whitening agent and an exfoliant |
US6228894B1 (en) * | 1998-04-17 | 2001-05-08 | Enhanced Derm Technologies, Inc. | Softgel-compatible composition containing retinol |
US6238683B1 (en) * | 1998-12-04 | 2001-05-29 | Johnson & Johnson Consumer Companies, Inc. | Anhydrous topical skin preparations |
US20020193321A1 (en) * | 2000-12-12 | 2002-12-19 | Mohan Vishnupad | Dual dispenser for aesthitically acceptable delivery of anhydrous skin treatment compositions |
ES2289315T3 (es) * | 2002-09-05 | 2008-02-01 | GALDERMA RESEARCH & DEVELOPMENT | Composicion despigmentante para la piel que contiene adapaleno y al menos un agente despigmentante. |
DE102004003478A1 (de) * | 2004-01-22 | 2005-08-18 | Basf Ag | Retinoid-haltige Zubereitungen |
FR2894474B1 (fr) * | 2005-12-12 | 2008-04-11 | Galderma Res & Dev | Gel depigmentant hydroalcoolique |
FR2915682B1 (fr) * | 2007-05-04 | 2009-07-03 | Galderma Res & Dev | Compositions depigmentantes dermatologiques et cosmetiques, leurs procedes de preparation, et leurs utilisations |
-
2008
- 2008-05-30 FR FR0853567A patent/FR2931661B1/fr not_active Expired - Fee Related
-
2009
- 2009-06-02 RU RU2010154235/15A patent/RU2010154235A/ru not_active Application Discontinuation
- 2009-06-02 WO PCT/FR2009/051036 patent/WO2009156675A2/fr active Application Filing
- 2009-06-02 AU AU2009264011A patent/AU2009264011A1/en not_active Abandoned
- 2009-06-02 EP EP09769516A patent/EP2293788A2/fr not_active Withdrawn
- 2009-06-02 CA CA2723435A patent/CA2723435A1/fr not_active Abandoned
- 2009-06-02 KR KR1020107029553A patent/KR20110015027A/ko not_active Application Discontinuation
- 2009-06-02 US US12/994,459 patent/US20110152372A1/en not_active Abandoned
- 2009-06-02 CN CN2009801200318A patent/CN102046161A/zh active Pending
- 2009-06-02 MX MX2010012754A patent/MX2010012754A/es not_active Application Discontinuation
- 2009-06-02 JP JP2011511070A patent/JP2011521933A/ja active Pending
Patent Citations (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3856934A (en) | 1970-06-24 | 1974-12-24 | A Kligman | Skin depigmentation |
US4581380A (en) | 1983-11-28 | 1986-04-08 | Groupement Economique dite: Centre National de Recherches Dermatologiques C.I.R.D. | 2,6-disubstituted naphthalene derivatives, a process for preparing the same and pharmaceutical and cosmetic compositions containing the same |
US4666941A (en) | 1983-11-28 | 1987-05-19 | Groupement Economique dit: Centre International de Recherces Dermatologiques C.I.R.D. | Pharmaceutical uses of substituted 6(5,6,7,8)tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2-naphthoic acid and its esters |
EP0199636A1 (fr) | 1985-04-11 | 1986-10-29 | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. Groupement d'Intérêt Economique dit: | Dérivés benzonaphtaléniques, leur procédé de préparation et leur application dans les domaines pharmaceutique et cosmétique |
EP0210929A2 (fr) | 1985-07-25 | 1987-02-04 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Dérivés aromatiques polycycliques, leur procédé de préparation et leur application dans les domaines pharmaceutique et cosmetique |
EP0232199A2 (fr) | 1986-01-21 | 1987-08-12 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Composés benzamido aromatiques, leur procédé de préparation et leur utilisation en médecine humaine ou vétérinaire et en cosmétique |
EP0260162A1 (fr) | 1986-07-17 | 1988-03-16 | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA Groupement d'Intérêt Economique dit: | Dérivés bicycliques aromatiques, leur procédé de préparation et leur utilisation en médecine humaine et vétérinaire et en cosmétique |
EP0292348A1 (fr) | 1987-04-30 | 1988-11-23 | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA Groupement d'Intérêt Economique dit: | Dérivés hétérocycliques polycycliques , leur procédé de préparation et leur utilisation en médecine humaine et vétérinaire |
EP0325540A1 (fr) | 1988-01-20 | 1989-07-26 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Esters et thioesters aromatiques, leur procédé de préparation et leur utilisation en médecine humaine ou vétérinaire et en cosmétique |
EP0359621A1 (fr) | 1988-09-01 | 1990-03-21 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Nouveau composé marqué au tritium, sa préparation et son application notamment dans la détermination de l'affinité des rétinoides pour leurs récepteurs nucléaires et leur protéine de liaison cytosolique |
EP0409728A2 (fr) | 1989-07-18 | 1991-01-23 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Esters bi-aromatiques, leur procédé de préparation et leur utilisation en médecine humaine ou vétérinaire et en cosmétique |
EP0409740A1 (fr) | 1989-07-20 | 1991-01-23 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveau composÀ© marqué au tritium, sa préparation et son application, notamment dans le repÀ©rage des récepteurs nucléaires des rétinoides |
EP0552282A1 (fr) | 1990-10-12 | 1993-07-28 | Cird Galderma | Composes bi-aromatiques et leur utilisation en medecine humaine et veterinaire et en cosmetique. |
EP0584191A1 (fr) | 1991-05-02 | 1994-03-02 | Cird Galderma | Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique. |
EP0514264A1 (fr) | 1991-05-13 | 1992-11-19 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Composés bi-aromatiques dérivés d'un motif salicylique, leur procédé de préparation et leur utilisation en médecine humaine et vétérinaire ainsi qu'en cosmétique |
EP0514269A1 (fr) | 1991-05-15 | 1992-11-19 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveaux composés aromatiques dérivés d'imine, leur procédé de préparation et leur utilisation en médecine humaine et vétérinaire ainsi qu'en cosmétique |
EP0658553A1 (fr) | 1993-12-15 | 1995-06-21 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0661258A1 (fr) | 1993-12-15 | 1995-07-05 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveaux composés propynyl bi-aromatiques, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0661260A1 (fr) | 1993-12-15 | 1995-07-05 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveaux composés bi-aromatiques dérivés d'amide, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0679628A1 (fr) | 1994-04-26 | 1995-11-02 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés polyéniques, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0679631A1 (fr) | 1994-04-26 | 1995-11-02 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Composés bi-aromatiques acétylénés à groupement adamantyle, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0679630A1 (fr) | 1994-04-26 | 1995-11-02 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés bicycliques-aromatiques, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0708100A1 (fr) | 1994-10-04 | 1996-04-24 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveaux composés dérivés du dibenzofuranne, compositions pharmaceutiques et cosmétiques les contenant |
EP0709382A1 (fr) | 1994-10-28 | 1996-05-01 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveaux composés dérivés aromatiques du dibenzofuranne, compositions pharmaceutiques et cosmétiques les contenant |
EP0722928A1 (fr) | 1995-01-20 | 1996-07-24 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés bicycliques-aromatiques à forte activité biologique, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0728739A1 (fr) | 1995-02-23 | 1996-08-28 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés bi-aromatiques dérivés d'amide, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0732328A1 (fr) | 1995-03-14 | 1996-09-18 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés hétérocycliques aromatiques, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0740937A2 (fr) | 1995-05-03 | 1996-11-06 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Utilisation de rétinoides pour la fabrication d'une composition cosmétique ou pharmaceutique |
EP0776881A1 (fr) | 1995-12-01 | 1997-06-04 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés biaromatiques portant un groupement adamantyl en para, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0776885A1 (fr) | 1995-12-01 | 1997-06-04 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés biaromatiques portant un groupement adamantyl en ortho, compositions pharmaceutiques et cosmétiques les contenant et utilisations |
EP0823903A1 (fr) | 1996-02-06 | 1998-02-18 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
EP0832057A1 (fr) | 1996-03-14 | 1998-04-01 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composes propynyl ou dienyl biaromatiques |
EP0832081A1 (fr) | 1996-03-14 | 1998-04-01 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Compos s bicycliques-aromatiques |
EP0816352A1 (fr) | 1996-06-28 | 1998-01-07 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Nouveaux composés biaryles hétérocycliques et leur utilisation en médecine humaine ou vétérinaire ainsi qu'en cosmétique |
EP0826657A1 (fr) | 1996-09-02 | 1998-03-04 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Nouveaux composés modulateurs des récepteurs hormonaux, les compositions les comprenant et leur utilisation en thérapie |
EP0874626A1 (fr) | 1996-09-20 | 1998-11-04 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation |
EP0934295A1 (fr) | 1996-10-23 | 1999-08-11 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Nouveaux derives bi-aromatiques du dibenzofuranne et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetique |
EP0915823A1 (fr) | 1996-11-19 | 1999-05-19 | Centre International De Recherches Dermatologiques Galderma - Cird Galderma | Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
EP0882033A1 (fr) | 1996-12-04 | 1998-12-09 | Centre International De Recherches Dermatologiques Galderma, ( Cird Galderma) | Derives d'acides benzofuranne-acryliques et leur utilisation comme modulateurs des recepteurs rxrs ou rars |
EP0850909A1 (fr) | 1996-12-31 | 1998-07-01 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés stilbéniques à groupement adamantyl, compositions les contenant et utilisations |
EP0879814A1 (fr) | 1997-05-23 | 1998-11-25 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Composés triaromatiques, compositions les contenant et utilisations |
WO1998056783A1 (fr) | 1997-06-13 | 1998-12-17 | Galderma Research & Development | Composes bi-aromatiques et compositions pharmaceutiques et cosmetiques les contenant |
WO1999010322A1 (fr) | 1997-08-21 | 1999-03-04 | Galderma Research & Development | Composes bi-aromatiques relies par un radical heteroethynylene et compositions pharmaceutiques et cosmetiques les contenant |
EP0952974A1 (fr) | 1997-08-21 | 1999-11-03 | Galderma Research & Development | Derives biphenyliques substitues par un radical aromatique ou heteroaromatique et compositions pharmaceutiques et cosmetiques les contenant |
EP0905118A1 (fr) | 1997-09-25 | 1999-03-31 | Galderma Research & Development, S.N.C. | Dérivés insaturés en position 4 du 6-tert-butyl-1,1-diméthylindane et leur utilisation en médicine humaine ou vétérinaire ainsi qu'en cosmétique |
EP0947496A1 (fr) | 1998-03-31 | 1999-10-06 | Galderma Research & Development, S.N.C. | Composés bicycliques-aromatiques et leur utilisation en médecine humaine ou vétérinaire ainsi qu'en cosmétologie |
WO1999050239A2 (fr) | 1998-03-31 | 1999-10-07 | Galderma Research & Development, S.N.C. | Nouveaux composes heteroethynylenes et compositions pharmaceutiques et cosmetiques les contenant |
WO1999065872A1 (fr) | 1998-06-12 | 1999-12-23 | Galderma Research & Development, S.N.C. | Composes diarylselenures et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetologie |
WO2005037772A2 (fr) | 2003-10-17 | 2005-04-28 | Galderma Research & Development, S.N.C. | NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS RARs, UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE |
WO2005056510A2 (fr) | 2003-12-08 | 2005-06-23 | Galderma Research & Development, S.N.C. | Nouveaux ligands activateurs des recepteurs rar s'utilisant en medecine et en cosmetique |
WO2005056516A1 (fr) | 2003-12-08 | 2005-06-23 | Galderma Research & Development, S.N.C. | Derives biphenyles utiles en tant que ligands d'activation des recepteurs rar, leur procede de preparation et leur utilisation en medecine humaine et en cosmetique |
US20060120979A1 (en) | 2004-12-02 | 2006-06-08 | Joel Rubin | Skin care composition comprising hydroquinone and a substantially anhydrous base |
WO2006066978A1 (fr) | 2004-12-23 | 2006-06-29 | Galderma Research & Development | Nouveaux ligands qui modulent les recepteurs rar, et leur utilisation en medecine et en cosmetique |
WO2007066041A2 (fr) | 2005-12-06 | 2007-06-14 | Galderma Research & Development | Composition dépigmentante de la peau comprenant un dérivé d'acide naphtoique |
Non-Patent Citations (2)
Title |
---|
JIMBOW K.: "N-acetyl4S cysteaminylphénol as a new type of depigmenting agent", ARCH. DERMATOL., vol. 127, no. 10, 19 July 1007 (1007-07-19), pages 1528 - 1534 |
JORGE L.; SANCHEZ, M.D.; MIGUEL VAZQUEZ, M.D, INTERNATIONAL JOURNAL OF DERMATOLOGY, vol. 21, 1061019, pages 55 58 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150147403A1 (en) * | 2012-06-01 | 2015-05-28 | Galderma Research & Development | Dermatological composition comprising oleosomes and retinoids, process for preparing the same and use thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2723435A1 (fr) | 2009-12-30 |
AU2009264011A1 (en) | 2009-12-30 |
CN102046161A (zh) | 2011-05-04 |
JP2011521933A (ja) | 2011-07-28 |
FR2931661A1 (fr) | 2009-12-04 |
MX2010012754A (es) | 2010-12-21 |
RU2010154235A (ru) | 2012-07-10 |
KR20110015027A (ko) | 2011-02-14 |
EP2293788A2 (fr) | 2011-03-16 |
US20110152372A1 (en) | 2011-06-23 |
WO2009156675A3 (fr) | 2010-04-08 |
FR2931661B1 (fr) | 2010-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2224908B1 (fr) | Compositions comprenant au moins un derive de l'acide naphtoïque, du peroxyde de benzoyle et au moins un agent filmogene. | |
EP1758588B1 (fr) | Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises. | |
FR2909000A1 (fr) | Compositions comprenant du peroxyde de benzoyle, au moins un derive de l'acide naphtoique et au moins un compose de type polymeres de polyurethane ou des derives de celui-ci, et leurs utilisations. | |
EP2125117A2 (fr) | Emulsion comprenant au moins un retinoide et du péroxyde de benzoyle | |
FR2901139A1 (fr) | Compositions comprenant au moins un derive de l'acide naphtoique et du peroxyde de benzoyle, leurs procedes de preparation, et leurs utilisations | |
WO2009156675A2 (fr) | Nouvelles compositions dépigmentantes sous forme d'une composition anhydre sans vaseline et sans élastomère comprenant un dérivé phénolique solubilisé et un rétinoïde | |
EP2291180A1 (fr) | Compositions depigmentantes anhydres comprenant, au sein de la phase grasse un derive phenolique solubilise et un retinoide | |
EP2293789A1 (fr) | Nouvelles compositions dépigmentantes sous forme d'une composition anhydre sans vaseline et sans élastomère comprenant un dérivé phénolique solubilisé | |
EP2291179A2 (fr) | Nouvelles compositions dépigmentantes anhydre comprenant un dérivé phénolique solubilisé |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980120031.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09769516 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009769516 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2723435 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2475/MUMNP/2010 Country of ref document: IN Ref document number: MX/A/2010/012754 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011511070 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009264011 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20107029553 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010154235 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2009264011 Country of ref document: AU Date of ref document: 20090602 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12994459 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI0907666 Country of ref document: BR Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE A PROCURACAO APRESENTADA NAO POSSUI DATA. SALIENTA-SE QUE TAL DOCUMENTO TEM QUE PREVER COMO OUTORGADO O PROCURADOR ORIGINAL DA ENTRADA NA FASE NACIONAL. |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI0907666 Country of ref document: BR Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AS DETERMINACOES REFERENTES A ENTRADA DO PEDIDO NA FASE NACIONAL E POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI NO 2387 DE 04/10/2016. |